TG Therapeutics, Inc. (TGTX)

Market Cap	2.20B
Revenue (ttm)	233.66M
Net Income (ttm)	12.67M
Shares Out	154.54M
EPS (ttm)	0.09
PE Ratio	158.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,213,857
Open	14.17
Previous Close	14.10
Day's Range	14.17 - 14.57
52-Week Range	6.46 - 35.67
Beta	2.32
Analysts	Strong Buy
Price Target	30.20 (+111.93%)
Earnings Date	May 7, 2024

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 264
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX

Analyst Forecast

According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $30.2, which is an increase of 111.93% from the latest price.

Price Target

$30.2

(111.93% upside)

Analyst Consensus: Strong Buy